The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Mohammad Luqman(Novartis (United States)), Anas Younes(Intercept Pharmaceuticals (United States))
Cited by 103
Related Papers
AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer
|Science Translational Medicine|2015|438
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
|Journal for ImmunoTherapy of Cancer|2018|286
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
|Journal of Clinical Oncology|2012|261